Research library

Key finding

Across two randomized phase 3 trials, bremelanotide significantly improved sexual desire and reduced related distress in premenopausal women with hypoactive sexual desire disorder.

Key finding

In a double-blind placebo-controlled study, intranasal PT-141 produced erectile responses in healthy men and men with mild-to-moderate erectile dysfunction.

Key finding

In women with hypoactive sexual desire disorder, melanocortin-4 receptor agonism increased activity in brain networks involved in sexual processing.

Key finding

Across female-rat models, bremelanotide increased solicitation and other centrally mediated sexual behaviours through defined melanocortin pathways.

Key finding

This review explains how bremelanotide engages central melanocortin-4 receptor pathways involved in sexual desire and arousal.

Key finding

The study reports that administration of PT-141 to rats and nonhuman primates results in penile erections.

Key finding

This preliminary evaluation suggests the potential for bremelanotide to positively affect desire and arousal in women with female sexual arousal disorder and indicates that bremelanotide is a promising candidate for further evaluation in an at-home study.

Key finding

PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate response to Viagra.

Key finding

Objective: To review data regarding bremelanotide, a recently approved therapy for hypoactive sexual desire disorder (HSDD).

Key finding

During the 52-week open-label extension of RECONNECT, no new safety signals were observed, and premenopausal women treated with bremelanotide exhibited sustained improvements in hypoactive sexual desire disorder symptoms.

Key finding

Hypoactive sexual desire disorder (HSDD) is a persistent deficiency or absence of sexual fantasies and desire resulting in significant distress or interpersonal difficulty.

Key finding

The authors reported that ambulatory monitoring was a useful methodology to detect small, transient increases in ambulatory BP accompanied by reductions in HR following bremelanotide.

Key finding

In premenopausal women with female sexual dysfunctions, self-administered, as desired, subcutaneous BMT was safe, effective, and well tolerated (NCT01382719).

Key finding

Kingsberg et al. described results from two 24-week Phase III trials of bremelanotide for treating hypoactive sexual desire disorder (HSDD) in women.

Key finding

INTRODUCTION: Erectile dysfunction (ED) pathophysiology involves complex interactions between vasculogenic, hormonal, and neurological mechanisms, with endothelial dysfunction and oxidative stress playing crucial roles.

Key finding

Clinicians must discern important distinctions between flibanserin, bremelanotide, and other agents when managing premenopausal HSDD.

Key finding

The US Food and Drug Administration (FDA) has approved two drugs for 'hypoactive sexual desire disorder' in women, flibanserin (Addyi) in 2015 and bremelanotide (Vyleesi) in 2019.

Key finding

Background: Hypoactive sexual desire disorder (HSDD) has a significant negative impact on women's overall health and relationships with their partners.

Key finding

The study reports that although a definitive physiology of HSDD is still unknown, multiple hormones and neurotransmitters likely participate in a dual-control model to balance excitation and inhibition of sexual desire.

Key finding

The study reports that treatment with BMT did not result in an increased frequency of treatment-emergent adverse events, and no participants discontinued the study because of adverse events.